Natera, Inc. $NTRA Shares Bought by Amundi

Key Points

• Amundi increased its stake in Natera, Inc. by 15.2% during the first quarter, acquiring an additional 65,728 shares, bringing its total ownership to approximately $69.2 million.
• Major institutional investors, including Vanguard Group and Price T Rowe Associates, have also significantly increased their positions in Natera, with Price T Rowe raising its stake by 56.3%.
• Natera's stock has received several positive ratings from analysts, with a consensus "Buy" rating and an average target price of $194.00, indicating strong market confidence in the company's growth potential.

Amundi increased its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 15.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 498,914 shares of the medical research company's stock after purchasing an additional 65,728 shares during the quarter. Amundi owned approximately 0.37% of Natera worth $69,204,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Fulton Bank N.A. grew its holdings in Natera by 2.0% in the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock valued at $516,000 after buying an additional 71 shares during the period. Compound Planning Inc. grew its holdings in Natera by 4.2% in the 1st quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company's stock valued at $271,000 after buying an additional 78 shares during the period. QRG Capital Management Inc. grew its holdings in Natera by 1.5% in the 1st quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock valued at $766,000 after buying an additional 81 shares during the period. Earned Wealth Advisors LLC grew its holdings in Natera by 5.0% in the 1st quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company's stock valued at $246,000 after buying an additional 82 shares during the period. Finally, Bridges Investment Management Inc. grew its holdings in Natera by 5.5% in the 1st quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company's stock valued at $237,000 after buying an additional 87 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent analyst reports. Stephens restated an "overweight" rating and issued a $183.00 price target on shares of Natera in a report on Friday, August 15th. Piper Sandler restated an "overweight" rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Cowen restated a "buy" rating on shares of Natera in a report on Friday, August 8th. Finally, Morgan Stanley reiterated an "overweight" rating and set a $195.00 target price on shares of Natera in a report on Sunday, August 10th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the stock. According to MarketBeat.com, Natera has a consensus rating of "Buy" and an average price target of $194.00.

Natera Stock Performance

Shares of NASDAQ:NTRA traded down $4.02 during trading on Friday, reaching $169.79. 192,069 shares of the stock were exchanged, compared to its average volume of 1,465,512. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $183.00. The firm has a market cap of $23.30 billion, a price-to-earnings ratio of -88.60 and a beta of 1.68. The firm's 50-day moving average price is $155.04 and its 200 day moving average price is $154.09.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business's revenue was up 32.2% on a year-over-year basis. During the same period last year, the firm posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 3,045 shares of the business's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer directly owned 65,430 shares of the company's stock, valued at approximately $8,990,082. The trade was a 4.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director directly owned 6,015 shares in the company, valued at $1,004,444.85. This trade represents a 31.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,423 shares of company stock worth $8,459,656 in the last ninety days. 5.63% of the stock is currently owned by company insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.